Impact of Valproate on Angiogenesis and Histone Deacetylation in Bladder Cancer
The goal of this study is to test whether the drug valproic acid can cause changes in bladder tumors that might inhibit their growth.
|Study Design:||Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science
|Official Title:||Impact of Valproate on Angiogenesis and Histone Deacetylation in Bladder Cancer|
- Thrombospondin-1 gene expression [ Time Frame: 1 day ] [ Designated as safety issue: No ]Expression of thrombospondin-1 will be assayed using quantitative real-time PCR and western blotting. Comparisons will be intra-patient for paired specimens acquired prior to and after treatment and inter-patient for treated and un-treated patients.
- Angiogenesis, proliferation, and histone deacetylase activity markers [ Time Frame: 1 day ] [ Designated as safety issue: No ]Histone deacetylase activity, angiogenesis, and proliferation markers will be assayed using qPCR and western blotting of tumor biopsy specimens. Comparisons will be intra-patient for paired specimens acquired prior to and after treatment and inter-patient for treated and un-treated patients.
|Study Start Date:||December 2011|
|Estimated Study Completion Date:||May 2013|
|Estimated Primary Completion Date:||May 2013 (Final data collection date for primary outcome measure)|
Experimental: valproic acid
Patients will be administered valproic acid (Depakote ER) for up to 30 days prior to tumor resection
Drug: Valproic Acid
500 mg orally, once daily for up to 30 days
Other Name: Depakote ER
Bladder cancer is the fourth most common cancer in the United States with over 60,000 new cases each year. It can usually be treated initially by insertion of an endoscope into the bladder and surgically removing the tumor, a procedure known as cystoscopy and trans-urethral resection of bladder tumor (TURBT). For most patients this procedure will successfully remove all of the detectable tumor. Unfortunately over 40% of all patients will develop a cancer recurrence in less than two years and all patients remain at increased risk of recurrence for the remainder of their lives. This risk requires life long monitoring and this is best accomplished with regular cystoscopic examinations. The goal of this study is to test whether the drug valproic acid can cause changes in bladder tumors that might inhibit their growth. Patients with suspected bladder cancer will be invited to participate in the study, if a tumor is observed during cystoscopy it will be sampled for research purposes and then according to standards of care, the patient scheduled for TURBT under general anesthesia. In the interval between discovery of a bladder tumor and resection, usually two to four weeks, the patient will be given valproic acid to take orally. In addition, tumors from patients with known or suspected bladder cancer referred for TURBT or cystectomy will be sampled. The tumor pieces obtained before and after taking valproic acid and from the referral patients not treated with valproic acid will be analyzed to see if the drug has changed what genes are active. We have found that valproic acid causes bladder cancer cells to make more of the protein, thrombospondin-1. This protein inhibits the growth of new blood vessels and so increased thrombospondin-1 in bladder tumors should inhibit their growth by decreasing the blood supply. Valproic acid may change thrombospondin-1 levels through inhibition of histone deacetylases. We will also assay HDAC activity in the tumor specimens. If valproic acid alters thrombospondin-1 levels and HDAC activity in bladder cancer patients further study to see if it can reduce growth will be justified. Valproic acid is a drug approved for the treatment of seizure disorders that is generally well tolerated with few side effects. It may prove useful in reducing bladder cancer recurrence and progression.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01738815
|United States, New York|
|SUNY Upstate Medical University||Recruiting|
|Syracuse, New York, United States, 13210|
|Contact: Jay E Reeder, Ph.D. 315-464-6104 email@example.com|
|Contact: Barbara McConnell 315-464-4473 firstname.lastname@example.org|
|Principal Investigator: Oleg Shapiro, M.D.|
|Principal Investigator: Gennady Bratslavsky, M.D.|
|Sub-Investigator: Jay E Reeder, Ph.D.|
|Principal Investigator:||Oleg Shapiro, MD||State University of New York - Upstate Medical University|